审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向:肿瘤细胞免疫 经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。 02 May 2024 Article accepted for publication. 29 Apr 2024 Submitting Author ** posted new comments in the Editor tab.(当天修回) Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下) 27 Apr 2024 Review of Review Editor 2 finalized. 23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments. 12 Apr 2024 Interactive review forum activated automatically. 07 Apr 2024 Reviewer 2: Minor revision is required. 07 Mar 2024 Review of Reviewer 1 is finalized. 08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None. 25 Nov 2023 Submitting Author ** resubmitted the manuscript. 23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据) 22 Nov 2023 Submitting Author ** submitted manuscript.
偏重的研究方向:肿瘤 经验分享:各位大佬,请问这个拒稿意见是什么意思啊? Reason: Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.
审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:肿瘤细胞免疫
经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。
02 May 2024 Article accepted for publication.
29 Apr 2024
Submitting Author ** posted new comments in the Editor tab.(当天修回)
Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)
27 Apr 2024 Review of Review Editor 2 finalized.
23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.
12 Apr 2024 Interactive review forum activated automatically.
07 Apr 2024 Reviewer 2: Minor revision is required.
07 Mar 2024 Review of Reviewer 1 is finalized.
08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.
25 Nov 2023 Submitting Author ** resubmitted the manuscript.
23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)
22 Nov 2023 Submitting Author ** submitted manuscript.
5
偏重的研究方向:肿瘤
经验分享:各位大佬,请问这个拒稿意见是什么意思啊?
Reason:
Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.
17
审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:肿瘤;生信
经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!
11 Apr 2023 Article accepted for publication.
07 Apr 2023 Review of Review Editor 3 finalized.
01 Apr 2023 Review of Review Editor 4 finalized.
30 Mar 2023 Review of Review Editor 1 finalized.
17 Mar 2023 Interactive review forum activated.
07 Feb 2023 submitted manuscript
108
审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:肿瘤
经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!
献上我的投稿过程,供以后的朋友参考:
24 Jan 2024 Article accepted for publication.
08 Jan 2024 Review of Review Editor 1 finalized.
07 Jan 2024 Review of Review Editor 2 finalized.
03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.
29 Dec 2023 Interactive review forum activated.
11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript.
34
审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:肿瘤;罕见基因变异;案例报道
经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!
2022.12.14号,提交Manuscript,Initial Validation
2022.12.19号,Editorial Assignment 稿件分配编辑
2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立
2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应
2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内
2023.03.16,Interactive review交互评审
2023.03.24,提交第一轮审稿意见和修改稿
2023.03.28,Review Finalized
2023.04.07,accepted
2023.04.12,Author's Proof,要求两天内提交
2023.04.25,支付版面费,2020 USD,限期一个月
2023.04.28,在线发表。
95
偏重的研究方向:肿瘤;免疫治疗;生信
经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…
19
审稿速度:1.0
偏重的研究方向:诊断;肿瘤;临床
经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新
31
审稿速度:24.0 | 投稿命中率:5.0
偏重的研究方向:肿瘤
经验分享:其实是很难的
23
审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向:肿瘤
经验分享:非常水……😌😌😌😌
58
审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
偏重的研究方向:肿瘤
经验分享:来还愿了
修回3天后审稿人全部endorse
第4天就直接accept了
从投稿到接收差不多两个月左右,这个速度简直感激
304